Endeavor

Top Moffitt Research Stories of 2024

From FDA approvals to drug discovery, Moffitt led the way this past year

Study Reveals Key Insights Between New Blood Condition and Lower-Risk Myelodysplastic Syndromes

High-risk CCUS patients by CHRS and CCRS risk stratification tools have similar characteristics and outcomes to patients with lower-risk MDS

Moffitt Experts Conduct First Analysis on New Criteria for Chronic Myelomonocytic Leukemia

Study finds patients who were switched to a chronic myelomonocytic leukemia diagnosis based on the new criteria more so resembled myelodysplastic syndromes genetically.

Moffitt Study Finds New Genetic Clues to Resistance in Multiple Myeloma Treatments

Study reveals genetic markers that predict treatment resistance, offering potential for more personalized therapy plans

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Personalized Vaccine Shows Promise in Early HER2-Positive Breast Cancer

Dendritic cell vaccine uses immune cells collected from the patient, which are enhanced in the lab and injected directly into the primary breast tumor

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Largest Comprehensive Study Compares Efficacy of CAR T Products for Multiple Myeloma

Cilta-cel demonstrates greater effectiveness than ide-cel but carries higher toxicities, study finds

Get to Know Moffitt Physician in Chief Dr. Karen Lu

Karen Lu, MD, is a nationally recognized physician-scientist who focuses her clinical and research interests on the surgical and medical treatment of women with ovarian and endometrial cancers